KCNA5 Gene Atrial Fibrillation Type 7 Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

Test Overview & Methodology

The KCNA5 gene test employs Next-Generation Sequencing to detect pathogenic and likely pathogenic variants associated with familial atrial fibrillation type 7, the most penetrant monogenic form of the arrhythmia. This molecular investigation provides definitive evidence of hereditary susceptibility, enabling cardiologists and genetic counsellors to implement targeted prevention, surveillance, and cascade screening for at-risk relatives.

Comparative Diagnostic Approaches

Physician Insight & Safety Protocols

Medication Advisory

Patient Safety & Exclusion Criteria

Patient FAQ & Clinical Guidance

1. What is the KCNA5 gene test and who should consider it?

The KCNA5 gene test detects pathogenic mutations that cause familial atrial fibrillation type 7, a monogenic form of the arrhythmia. It is recommended for patients with early-onset atrial fibrillation diagnosed before age 55, those with a confirmed family history of atrial fibrillation or sudden cardiac death, and individuals who develop atrial fibrillation without typical risk factors such as hypertension or valvular disease. A negative result does not exclude other genetic or acquired forms of atrial fibrillation.

2. What does the 2800 AED price include and can insurance be used?

The 2800 AED fee covers end-to-end KCNA5 NGS sequencing, bioinformatic analysis, clinical interpretation by a DHA-licensed consultant medical geneticist, telephonic genetic counselling, and ISO-certified cold-chain sample collection via VIP Mobile Phlebotomy. Direct insurance billing verification is available before the test via WhatsApp at +971 54 548 8731. Many UAE health plans cover medically indicated genetic testing for hereditary arrhythmia syndromes.

3. How soon are results delivered and who interprets them?

Results are issued within 3 to 4 weeks after the laboratory receives your sample. The report is interpreted by our DHA-licensed clinical team led by Consultant Medical Genetics Lina Osama Zaki Quteineh. It includes a clear classification of any detected variant — pathogenic, likely pathogenic, or variant of uncertain significance — along with family risk estimates and actionable recommendations. A private telephonic consultation is scheduled to walk through the findings and answer all questions.

4. Is home sample collection available for this genetic test?

Yes. Because this test requires peripheral whole blood, our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service is available daily from 8 AM to 11 PM. A trained phlebotomist visits your home, collects the sample under sterile conditions, and transports it directly to the ISO 9001:2015 accredited laboratory using certified cold-chain protocols to maintain specimen integrity.

5. What happens if a variant of uncertain significance is found?

If a variant of uncertain significance (VUS) is identified, our team conducts an in-depth bioinformatic re-evaluation and, if clinically warranted, may recommend segregation studies in family members. The result is always discussed during a telephonic counselling session to clarify the current evidence and outline next steps. Periodic reclassification of VUS results is provided as new scientific data emerges.

UAE Regulatory & Data Privacy Adherence

Clinical & Logistical Metadata